Geron Corporation filed a current report on Form 8-K on October 28, 2026, disclosing that it issued a press release providing an update on the Phase 3 IMpactMF clinical trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis.

Key Highlights

  • Trial update announced: Geron Corporation reported an update on the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis.
  • Drug under evaluation: The trial involves imetelstat as the investigational therapy.
  • Patient population: The trial focuses on patients with JAK inhibitor relapsed/refractory myelofibrosis.
  • Press release attached: The update was delivered via a press release dated October 28, 2026, filed as Exhibit 99.1.
  • Signing officer: The filing was signed by Timothy Williams, Executive Vice President, Chief Legal Officer and Corporate Secretary.

Geron Reports Phase 3 IMpactMF Clinical Trial Update on October 28, 2026

Geron Corporation (NASDAQ:GERN), a biopharmaceutical company incorporated in Delaware and headquartered in Foster City, California, filed a current report disclosing that on October 28, 2026, it issued a press release providing an update on its Phase 3 IMpactMF clinical trial. According to the filing, the trial is evaluating imetelstat in patients with JAK inhibitor relapsed/refractory myelofibrosis.

The filing, made under Item 8.01 (Other Events) of Form 8-K, incorporates by reference a press release titled "Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis," dated October 28, 2026, which was attached as Exhibit 99.1. The filing does not reproduce the substantive content of the press release within the body of the 8-K itself; the press release is the primary vehicle for the disclosed update.

The report was signed on behalf of Geron Corporation by Timothy Williams, identified in the filing as Executive Vice President, Chief Legal Officer and Corporate Secretary. Geron's common stock, with a par value of $0.001, is listed on The Nasdaq Stock Market LLC under the trading symbol GERN, as stated on the cover page of the filing.

What Was Disclosed

Geron Corporation filed an 8-K on October 28, 2026, to report an update on the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis, with the full update contained in the attached press release, Exhibit 99.1.